(Q34975026)

5 August 2017

title

The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold (English)

1 reference

5 August 2017

2

Christopher J Winrow

1 reference

5 August 2017

Anthony L Gotter

1

1 reference

5 August 2017

Joseph Brunner

3

1 reference

5 August 2017

Susan L Garson

4

1 reference

5 August 2017

Steven V Fox

5

1 reference

5 August 2017

Jacquelyn Binns

6

1 reference

5 August 2017

Charles M Harrell

7

1 reference

5 August 2017

Donghui Cui

8

1 reference

5 August 2017

Ka Lai Yee

9

1 reference

5 August 2017

Mark Stiteler

10

1 reference

5 August 2017

Joanne Stevens

11

1 reference

5 August 2017

Alan Savitz

12

1 reference

5 August 2017

Pamela L Tannenbaum

13

1 reference

5 August 2017

Spencer J Tye

14

1 reference

5 August 2017

Terrence McDonald

15

1 reference

5 August 2017

Leon Yao

16

1 reference

5 August 2017

Scott D Kuduk

17

1 reference

5 August 2017

Jason Uslaner

18

1 reference

5 August 2017

Paul J Coleman

19

1 reference

5 August 2017

John J Renger

20

1 reference

5 August 2017

language of work or name

1 reference

28 August 2013

1 reference

5 August 2017

1 reference

5 August 2017

volume

14

1 reference

5 August 2017

page(s)

90

1 reference

Quantitative electroencephalography within sleep/wake states differentiates GABAA modulators eszopiclone and zolpidem from dual orexin receptor antagonists in rats

5 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765993

8 July 2018

Insomnia pharmacotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765993

Orexin receptors as therapeutic drug targets

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765993

Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765993

International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin receptor function, nomenclature and pharmacology

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765993

Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765993

Pharmacological characterization of MK-6096 - a dual orexin receptor antagonist for insomnia

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765993

Sleep neurobiology from a clinical perspective

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765993

Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765993

Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765993

Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765993

The role of imaging in proof of concept for CNS drug discovery and development

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765993

A physiologic basis for the evolution of pharmacotherapy for insomnia

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765993

Promotion of sleep by targeting the orexin system in rats, dogs and humans

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765993

Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765993

Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765993

To eat or to sleep? Orexin in the regulation of feeding and wakefulness

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765993

The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765993

Orexin A activates locus coeruleus cell firing and increases arousal in the rat.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765993

Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765993

The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765993

Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765993

The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765993

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765993

Diurnal variation in orexin A immunoreactivity and prepro-orexin mRNA in the rat central nervous system.

8 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2202-14-90

Antagonism of rat orexin receptors by almorexant attenuates central chemoreception in wakefulness in the active period of the diurnal cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2202-14-90

Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2202-14-90

Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2202-14-90

Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2202-14-90

Functional and binding kinetic studies make a distinction between OX1 and OX2 orexin receptor antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2202-14-90

Orexin receptor antagonists differ from standard sleep drugs by promoting sleep at doses that do not disrupt cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2202-14-90

Increased hypocretin-1 (orexin-a) levels in cerebrospinal fluid of rats after short-term forced activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2202-14-90

Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2202-14-90

Hypocretin (orexin) deficiency in human narcolepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2202-14-90

Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2202-14-90

Sex differences and the effect of gaboxadol and zolpidem on EEG power spectra in NREM and REM sleep.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2202-14-90

Differential effects of the dual orexin receptor antagonist almorexant and the GABA(A)-α1 receptor modulator zolpidem, alone or combined with ethanol, on motor performance in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2202-14-90

Sub-chronic administration of zolpidem affects modifications to rat sleep architecture

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2202-14-90

The selective extrasynaptic GABAA agonist, gaboxadol, improves traditional hypnotic efficacy measures and enhances slow wave activity in a model of transient insomnia.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765993

Circadian and Homeostatic Regulation of Hypocretin in a Primate Model: Implications for the Consolidation of Wakefulness

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765993

Central benzodiazepine receptor occupancy by zolpidem in the human brain as assessed by positron emission tomography

26 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23981345

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

An alternative method of chronic cerebrospinal fluid collection via the cisterna magna in conscious rhesus monkeys

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23981345

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-2202-14-90

1 reference

Dimensions Publication ID

5 August 2017

0 references

1 reference

5 August 2017

1 reference